Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Abramson Cancer Center at Penn Medicine
Sun Yat-sen University
University of Iowa
Second Affiliated Hospital of Zunyi Medical University
Beijing Chest Hospital, Capital Medical University
Actuate Therapeutics Inc.
Celgene
Tang-Du Hospital
Rutgers, The State University of New Jersey
Henan Cancer Hospital
Columbia University
Peking University First Hospital
Columbia University
AIO-Studien-gGmbH
Tang-Du Hospital
Alliance Foundation Trials, LLC.
Wake Forest University Health Sciences
Second Affiliated Hospital, School of Medicine, Zhejiang University
Radiation Therapy Oncology Group
Henry Ford Health System
GU Research Network, LLC
Abramson Cancer Center at Penn Medicine
University of Washington
Sun Yat-sen University
Sichuan Cancer Hospital and Research Institute
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
University of Pittsburgh
UNC Lineberger Comprehensive Cancer Center
Celgene
Kobe Minimally Invasive Cancer Center
Peking Union Medical College
Celgene
West Virginia University
Gruppo Oncologico Italiano di Ricerca Clinica
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
HiberCell, Inc.
First People's Hospital of Hangzhou
Tongji University